ANI Pharmaceuticals Overview
- Year Founded
-
1996
- Status
-
Public
- Employees
-
642
- Stock Symbol
-
ANIP
- Investments
-
29
- Share Price
-
$56.15
- (As of Thursday Closing)
ANI Pharmaceuticals General Information
Description
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
Contact Information
Website
www.anipharmaceuticals.comCorporate Office
- 210 Main Street West
- Baudette, MN 56623
- United States
Corporate Office
- 210 Main Street West
- Baudette, MN 56623
- United States
ANI Pharmaceuticals Timeline
ANI Pharmaceuticals Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $56.15 | $54.32 | $48.20 - $70.81 | $1.18B | 21M | 312K | $1.19 |
ANI Pharmaceuticals Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 1,406,893 | 1,243,981 | 957,468 | 958,187 |
| Revenue | 538,953 | 486,816 | 316,385 | 216,136 |
| EBITDA | 116,690 | 106,612 | 25,040 | 3,164 |
| Net Income | 27,015 | 18,779 | (47,896) | (42,603) |
| Total Assets | 920,753 | 904,422 | 760,087 | 771,598 |
| Total Debt | 285,244 | 285,669 | 286,519 | 287,370 |
ANI Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
ANI Pharmaceuticals Comparisons
Industry
Financing
Details
0000 0
000000
ANI Pharmaceuticals Competitors (22)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Taro Pharmaceutical Industries | Corporate Backed or Acquired | Haifa Bay, Israel | 0000 | 0000 | 00000000000 | |
| Lannett | Corporation | Trevose, PA | 000 | 00000 | 0000000000. | |
| Padagis | Private Equity-Backed | Allegan, MI | 0000 | 00.000 | 000000000 | 00.000 |
| Mallinckrodt | Formerly PE-Backed | Dublin, Ireland | 0000 | 00.00 | 0000000000. | |
| GlaxoSmithKline Consumer Nigeria | Corporation | Lagos, Nigeria | 00 | 00000000 |
ANI Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
ANI Pharmaceuticals Patents
ANI Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-11975047-B1 | Methods for storing and warming purified corticotropin compositions | Active | 28-Oct-2022 | 00000000000 | 00 |
| US-20240189229-A1 | Liquid pharmaceutical compositions of baclofen for oral administration | Inactive | 19-Oct-2022 | 0000000000 | |
| US-20220347140-A1 | Stable oral suspensions of baclofen | Active | 23-Apr-2021 | 0000000000 | 0 |
| US-11564898-B1 | Stable oral suspensions of baclofen | Active | 23-Apr-2021 | 0000000000 | 0 |
| US-11484518-B1 | Stable oral suspensions of baclofen | Active | 23-Apr-2021 | A61K31/197 | 0 |
ANI Pharmaceuticals Executive Team (18)
| Name | Title | Board Seat |
|---|---|---|
| Nikhil Lalwani | Chief Executive Officer & Board Member | |
| Stephen Carey | Senior Vice President and Chief Financial Officer | |
| Muthusamy Shanmugam | Chief Operating Officer, Operations & Board Member | |
| Krista Davis | Executive & Senior Vice President | |
| Christopher Mutz | Head of Rare Disease |
ANI Pharmaceuticals Board Members (10)
| Name | Representing | Role | Since |
|---|---|---|---|
| 0000000 0000 | Self | Board Member | 000 0000 |
| 000000 000000 | Self | Board Member | 000 0000 |
| 000000000 00000000 | ANI Pharmaceuticals | Chief Operating Officer, Operations & Board Member | 000 0000 |
| 000000 0000000 | ANI Pharmaceuticals | Chief Executive Officer & Board Member | 000 0000 |
| 0000000 0. 00000 | Self | Chairman of the Board and Member of Compensation Committee | 000 0000 |
ANI Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
ANI Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
ANI Pharmaceuticals Investments & Acquisitions (29)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Alimera Sciences | 24-Jun-2024 | 0000000000 | 00000 | Pharmaceuticals | 000000 00 |
| Alvogen (Certain Pharmaceutical Products Rights in Morristown, New Jersey) | 27-Dec-2023 | 000000000 | 000 | Buildings and Property | |
| Slayback Pharma (ANDA, Registered Patents and Patent Applications in Princeton, New Jersey) | 14-Aug-2023 | 000000000 | 000 | Buildings and Property | |
| Akorn (ANDA Assets) | 15-Jun-2023 | 000000000 | Buildings and Property | ||
| Oakrum Pharma (Portfolio Four Abbreviated New Drug Applications) | 21-Jul-2022 | Corporate Asset Purchase | Buildings and Property | 000000 00 |
ANI Pharmaceuticals Subsidiaries (2)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| ANI Pharmaceuticals Canada | Pharmaceuticals | Oakville, Canada | 2018 |
| Novitium | Pharmaceuticals | East Windsor, NJ | 0000 |
ANI Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated November, 21, 2023
36.26 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 16,009
Rank
Percentile
Pharmaceuticals
Industry
00 of 909
Rank
Percentile
Pharmaceuticals
Subindustry
00 of 446
Rank
Percentile
ANI Pharmaceuticals FAQs
-
When was ANI Pharmaceuticals founded?
ANI Pharmaceuticals was founded in 1996.
-
Who is the CEO of ANI Pharmaceuticals?
Nikhil Lalwani is the CEO of ANI Pharmaceuticals.
-
Where is ANI Pharmaceuticals headquartered?
ANI Pharmaceuticals is headquartered in Baudette, MN.
-
What is the size of ANI Pharmaceuticals?
ANI Pharmaceuticals has 642 total employees.
-
What industry is ANI Pharmaceuticals in?
ANI Pharmaceuticals’s primary industry is Pharmaceuticals.
-
Is ANI Pharmaceuticals a private or public company?
ANI Pharmaceuticals is a Public company.
-
What is ANI Pharmaceuticals’s stock symbol?
The ticker symbol for ANI Pharmaceuticals is ANIP.
-
What is the current stock price of ANI Pharmaceuticals?
As of 12-Sep-2024 the stock price of ANI Pharmaceuticals is $56.15.
-
What is the current market cap of ANI Pharmaceuticals?
The current market capitalization of ANI Pharmaceuticals is $1.18B.
-
What is ANI Pharmaceuticals’s current revenue?
The trailing twelve month revenue for ANI Pharmaceuticals is $539M.
-
Who are ANI Pharmaceuticals’s competitors?
Taro Pharmaceutical Industries, Lannett, Padagis, Mallinckrodt, and GlaxoSmithKline Consumer Nigeria are some of the 22 competitors of ANI Pharmaceuticals.
-
What is ANI Pharmaceuticals’s annual earnings per share (EPS)?
ANI Pharmaceuticals’s EPS for 12 months was $1.19.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
